{"filing":{"accession_number":"0001477449-26-000036","cik":"0001477449","ticker":"TDOC","company_name":"Teladoc Health, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"tdoc-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1477449/000147744926000036/tdoc-20260729.htm"},"events":[{"id":21593,"run_id":19480,"accession_number":"0001477449-26-000036","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a standard earnings release disclosing Teladoc Health's Q2 2026 financial results, including revenue of $606.9 million (down 4% YoY), net loss of $38.9 million ($0.21 per share), and adjusted EBITDA of $65.7 million (down 5% YoY). The press release is attached as Exhibit 99.1 and includes detailed segment performance, cash flow metrics, and forward guidance for Q3 and full-year 2026, which is the typical format and content of a material earnings disclosure under Item 2.02.","company_name":"Teladoc Health, Inc.","ticker":"TDOC","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21269,"accession_number":"0001477449-26-000036","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing Teladoc Health's Q2 2026 financial results, including revenue of $606.9 million (down 4% YoY), net loss of $38.9 million ($0.21 per share), and adjusted EBITDA of $65.7 million (down 5% YoY). The press release is attached as Exhibit 99.1 and includes detailed segment performance, cash flow metrics, and forward guidance for Q3 and full-year 2026, which is the typical format and content of a material earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:09:45.192895+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21269,"accession_number":"0001477449-26-000036","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing Teladoc Health's Q2 2026 financial results, including revenue of $606.9 million (down 4% YoY), net loss of $38.9 million ($0.21 per share), and adjusted EBITDA of $65.7 million (down 5% YoY). The press release is attached as Exhibit 99.1 and includes detailed segment performance, cash flow metrics, and forward guidance for Q3 and full-year 2026, which is the typical format and content of a material earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:09:45.192895+00:00","company_name":"Teladoc Health, Inc.","ticker":"TDOC","filing_date":"2026-07-29"}]}